News &amp; Updates

Men with reduced fertility at risk of testicular, prostate cancers

Male infertility is linked to increased susceptibility to malignancies in the testicles or prostate, as shown in a study.

Men with reduced fertility at risk of testicular, prostate cancers

Telemedicine-delivered CBT feasible for treating poststroke anxiety

Remote delivery of cognitive behavioural therapy (CBT) shows potential in the management of anxiety among stroke survivors, according to the results of a feasibility study.

Telemedicine-delivered CBT feasible for treating poststroke anxiety

Single-tablet regimen boosts virologic response in acute/early HIV-1 infection

14 Aug 2020 by

Rapid treatment initiation with a single-tablet regimen comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) demonstrated a high virological response rate in patients with acute or early HIV-1* infection, according to a subgroup analysis of the DIAMOND** study presented at AIDS 2020.

Single-tablet regimen boosts virologic response in acute/early HIV-1 infection

Relugolix combo therapy could reduce HMB-related anaemia, distress

Relugolix combination therapy (relugolix-CT) comprising relugolix and estradiol (E2)/norethindrone acetate (NETA) could improve anaemia in women with heavy menstrual bleeding (HMB) due to uterine fibroids, according to pooled results of the phase III LIBERTY* 1 and 2 trials presented at ESHRE 2020.

Relugolix combo therapy could reduce HMB-related anaemia, distress

Plasma riboflavin may be a marker for ESCC outcomes

Plasma riboflavin levels may be a good indicator of prognosis in patients with oesophageal squamous cell carcinoma (ESCC), a recent study has shown.

Plasma riboflavin may be a marker for ESCC outcomes

Switching to B/F/TAF maintains viral suppression in HIV+ elderly

Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.

Switching to B/F/TAF maintains viral suppression in HIV+ elderly

Starting lipid-lowering therapy for ASCVD prevention: How early and in whom?

Intensive cholesterol-lowering therapy yields substantial reductions in the risk of atherosclerotic cardiovascular disease (ASCVD) over a 30-year period. This can be achieved if therapy is initiated in individuals in their 40s and 50s with nonhigh-density lipoprotein cholesterol (non-HDL-C) levels at least 160 mg/dL, according to a team of researchers.

Starting lipid-lowering therapy for ASCVD prevention: How early and in whom?

Charlson Comorbidity Index a valuable tool in estimating renal cell carcinoma prognosis

Use of the Charlson Comorbidity Index (CCI) appears to be beneficial for assessing prognosis and optimizing therapy in patients with advanced renal cell carcinoma who are receiving first-line sunitinib or pazopanib, suggests a recent study.

Charlson Comorbidity Index a valuable tool in estimating renal cell carcinoma prognosis

Statins may protect against C. difficile infections

Use of statins appears to confer a protective benefit against the development of Clostridium difficile infection (CDI) and improve CDI treatment success, according to a study. However, its benefit on mortality remains unclear.

Statins may protect against C. difficile infections